- Brii Biosciences has entered into a license & technology transfer agreement with Joincare to develop & commercialize BRII-693 in the Greater China region
- As per the deal, Joincare will handle development, regulatory activities & commercialization of BRII-693 in Greater China in exchange for an upfront payment as well as development & commercial milestones, with net sales-based tiered royalties, whereas Brii will retain its rights in the rest of the world
- BRII-693 is a novel synthetic lipopeptide that targets MDR/XDR gram-negative bacterial infections caused by carbapenem-resistant A. baumannii, P. aeruginosa & Enterobacterales, which showed favorable safety & PK in P-I trial
Ref: Prnewswire| Image: Brii Biosciences & Joincare Pharmaceutical | Press Release
Related News:- Brii Bio Signs an Agreement with VBI Vaccines to Acquire BRII-179’s IP Rights
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
